Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating the safety and preliminary efficacy of 10-Propargyl-10-Deazaaminopterin in recurrent or refractory lymphoma (non-Ho…
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG [Phase 1, Phase 2]
Phase 1/2 trial update for 90Y-hLL2 IgG in Non-Hodgkin's Lymphoma shows completed status.
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 safety study evaluating different doses of hA20 (Veltuzumab) in CD20+ non-Hodgkin's lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of hA20 (humanized anti-CD20) in CD20+ non-Hodgkin's lymphoma completed.
-
EMA withdrawal · 2021-08-16EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Safety Study of NHL With 90Y-hLL2 IgG [Phase 1, Phase 2]
A Phase 1/Phase 2 safety study of 90Y-hLL2 IgG in non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating monoclonal antibodies for detecting residual disease in patients treated for non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL [Phase 1, Phase 2]
Clinical trial update for subcutaneously administered veltuzumab (hA20) in non-Hodgkin lymphoma and chronic lymphocytic leukemia; study comp…
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 2]
Phase 2 study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in relapsed/refractory indolent non-Hodgkin's lymphoma; study completed with…
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating CD19/22 CAR-T cells combined with a PD-1 inhibitor in relapsed/refractory B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating Venetoclax in Subjects With Hematological Malignancies [Phase 1, Phase 2]
Clinical trial update for venetoclax in hematological malignancies at phases 1 and 2; study status completed.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating carfilzomib and TGR-1202 in relapsed/refractory lymphoma and Hodgkin disease, terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial update for ADCT-301 in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.
-
FDA approval · 2021-06-14FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)
The FDA approved a supplemental application for TREXALL (methotrexate) filed by Teva Women's Health, Inc.
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies [NA]
A completed clinical trial evaluating intensity modulated total marrow irradiation (IM-TMI) for advanced hematologic malignancies, with resu…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients [Phase 2]
Phase 2 trial evaluating OFATUMUMAB within a reduced intensity conditioning regimen for high-risk B-cell non-Hodgkin lymphoma patients; stud…
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial investigating azacytidine, bendamustine, and piamprizumab in refractory/relapsed B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating combination chemotherapy with or without rituximab in older adults with non-Hodgkin's lymphoma; completed study.
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating combination chemotherapy followed by radiation therapy for aggressive non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial investigated outpatient administration of R-DHAP in relapsed or refractory non-Hodgkin lymphoma; status completed.
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma [NA]
Clinical trial update describing a study of bortezomib and filgrastim to promote stem cell mobilization in patients with various B-cell non-…